Naltrexone Patents -Hx of LDN

[Guest guest]

Hi all, I first posted on the topic of naltrexone patents in:

low dose naltrexone/message/28844

The history of LDN does not appear complete without knowing why for

example the Patent Assignee: Baker Cummins Pharmaceuticals, Inc.

(Miami, FL) did not pursue naltrexone for its several patents including:

Autoimmune-naltrexone Patent from 1989! :

http://snipurl.com/hfux

MS-naltrexone patent from 1991! :

http://snipurl.com/hfv0

All 6 Patents with Assignee: Baker Cummins Pharmaceuticals, Inc.

(Miami, FL) :

http://snipurl.com/hr4u

So why not Baker?

http://informagen.com/Resource_Informagen/report.php?mrn=902 :

Subsidiary " Baker Norton is also engaged in the research, development

and manufacture of pharmaceuticals. In brand name products, it focuses

on new compounds that address unmet clinical needs. In generics, its

strategy is to select difficult-to-formulate drugs with significant

market potential. "

If LDN/naltrexone protocols no longer fit its corporate strategy at

some time, I'm still a bit surprised it did not find some other

corporate entity with interest capable of utilizing it - particularly

as their 1989 Naltrexone method of treatment for autoimmune diseases

patent states:

1) " All of the currently practiced drug treatments' `have significant

drawbacks' "

2) " Continuing therapy with any or all of the aforementioned

categories of drugs can produce a variety of well-known adverse

effects, and none of these drugs are significantly effective in

achieving true remission of the disease in most patients. "

3) " The method of the present invention not only provides dramatic

symptomatic relief for patients suffering from autoimmune diseases'but

has been found to reduce the patient's systemic autoantibody level,

potentially leading to a true remission in the course of the disease. "

4) " There have been few reports of any significant adverse effects

with nalmefene or naltrexone therapy at the dosage levels proposed by

the present invention, unlike many of the pharmaceutical agents which

have been conventionally used to treat autoimmune diseases. "

Anyone here know about this historical context? I suspect it possible

Dr. Bihari may have communicated with them as his MS-naltrexone patent

references their 1991 MS-naltrexone patent. Ideally any inquiry into

this should be done diplomatically (perhaps someone already in touch

with http://www.ldninfo.org or Dr. Bihari could be emailed first as we

may have an adequate answer there).

http://www.ivaxpharmaceuticals.com/aboutus.html

http://www.ivaxpharmaceuticals.com/product_offering.html

Compare aforementioned patent links to Dr. Bihari's naltrexone patents:

http://snipurl.com/hr51

Note: Dosing range discrepancies

Dr. Bihari appears to have shared more of his clinical experiences

with this approach and may/likely represent/s a refinement of approach.

Medical discoveries/leads are increasingly appearing more often first

in patent databases (e.g. http://www.uspto.gov &

http://ep.espacenet.com ) than in peer reviewed medical journal

databases (e.g. http://pubmed.gov) perhaps because once it is widely

published it can threaten patentability; and unfortunately the patent

process can take years. Once the patent is finally published however

it becomes accessible to the public although the patent holder has

legal rights over its commercialization. {Note: I'm not a patent

lawyer & this is just my current understanding.}

Best Wishes to all & please share any interesting leads/thoughts, Josh

Some References:

US Patent #: 4,857,533

US Patent #: 4,994,466

US Patent #: 6,586,443